{"DataElement":{"publicId":"3446967","version":"1","preferredName":"Leiomyosarcoma and Endometrial Stromal Sarcoma American Joint Committee on Cancer (AJCC) Edition 7 Group Stage","preferredDefinition":"Stage group determined from information on the tumor (T), regional node (N) and metastases (M) and by grouping cases with similar prognosis for leiomyosarcoma and endometrial stromal sarcoma.","longName":"3444912v1.0:3446558v1.0","context":"NCI Standards","contextVersion":"1","DataElementConcept":{"publicId":"3444912","version":"1","preferredName":"Leiomyosarcoma and Endometrial Stromal Sarcoma Stage Grouping","preferredDefinition":"A malignant mesenchymal tumor arising from the wall of the uterine corpus (uterine body).  The most representative examples are leiomyosarcoma and endometrial stromal sarcoma. -- 2004_An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage.","longName":"3444898v1.0:2230143v1.0","context":"NCIP","contextVersion":"1","ObjectClass":{"publicId":"3444898","version":"1","preferredName":"Uterine Corpus Sarcoma","preferredDefinition":"A malignant mesenchymal tumor arising from the wall of the uterine corpus (uterine body).  The most representative examples are leiomyosarcoma and endometrial stromal sarcoma. -- 2004","longName":"C6339","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Uterine Corpus Sarcoma","conceptCode":"C6339","definition":"A malignant mesenchymal neoplasm arising from the wall of the uterine corpus (uterine body).  The most representative examples are leiomyosarcoma and endometrial stromal sarcoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BEFC61B5-2A74-B731-E040-BB89AD4344A0","latestVersionIndicator":"Yes","beginDate":"2012-05-01","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-05-01","modifiedBy":"ONEDATA","dateModified":"2012-05-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2230143","version":"1","preferredName":"Stage Grouping","preferredDefinition":"Stage Grouping; an assessment based on the combined evaluation of the patient's T stage, M stage, and N stage. (caDSR)","longName":"C38027","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage Grouping","conceptCode":"C38027","definition":"An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage, as well as prognostic parameters for specific cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F752037A-4CC2-36A8-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-18","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-05-18","modifiedBy":"ONEDATA","dateModified":"2005-05-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BEFC61B5-2B5A-B731-E040-BB89AD4344A0","latestVersionIndicator":"Yes","beginDate":"2012-05-01","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-05-01","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":"Created for CRF standard harmonization. Released per final community approval. mc 5/7/12","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3446558","version":"1","preferredName":"Leiomyosarcoma and Endometrial Stromal Sarcoma American Joint Committee on Cancer (AJCC) Edition 7 Group Stage","preferredDefinition":"A malignant mesenchymal tumor arising from the wall of the uterine corpus (uterine body).  The most representative examples are leiomyosarcoma and endometrial stromal sarcoma. -- 2004_A group formed for the purpose of developing a system of clinical staging for cancer that is acceptable to the American medical profession and is compatible with other accepted classifications._An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage._The extent of a cancer within the body, especially whether the disease has spread from the original site to other parts of the body.","longName":"3446558v1.0","context":"NCIP","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"13","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Stage unknown","valueDescription":"Stage Unknown","ValueMeaning":{"publicId":"3357508","version":"1","preferredName":"Stage Unknown","longName":"3357508","preferredDefinition":"A finding indicating that the extent of organ/tissue involvement by a malignant neoplasm is not reported or not assessed.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage Unknown","conceptCode":"C92207","definition":"The extent of organ/tissue involvement by a malignant neoplasm is not reported or not assessed.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B6D76279-6263-2CA8-E040-BB89AD434A54","latestVersionIndicator":"Yes","beginDate":"2012-01-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BEFE6466-3362-1A35-E040-BB89AD4368E7","beginDate":"2012-05-01","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-05-01","modifiedBy":"ONEDATA","dateModified":"2012-05-01","deletedIndicator":"No"},{"value":"I","valueDescription":"Stage I Uterine Sarcoma","ValueMeaning":{"publicId":"3446560","version":"1","preferredName":"Stage I Uterine Sarcoma","longName":"3446560","preferredDefinition":"Stage I includes: T1, N0, M0.  T1: Tumor limited to the uterus.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  This staging applies to leiomyosarcoma, endometrial stromal sarcoma, and adenosarcoma. (AJCC 7th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage I Uterine Sarcoma AJCC v7","conceptCode":"C8258","definition":"Stage I includes: T1, N0, M0.  T1: Tumor limited to the uterus.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  This staging applies to leiomyosarcoma, endometrial stromal sarcoma, and adenosarcoma. (AJCC 7th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BEFD3837-B66E-9AD8-E040-BB89AD431C21","latestVersionIndicator":"Yes","beginDate":"2012-05-01","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-05-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BEFD3837-B687-9AD8-E040-BB89AD431C21","beginDate":"2012-05-01","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-05-01","modifiedBy":"ONEDATA","dateModified":"2012-05-01","deletedIndicator":"No"},{"value":"IA","valueDescription":"Stage IA Uterine Sarcoma","ValueMeaning":{"publicId":"3446562","version":"1","preferredName":"Stage IA Uterine Sarcoma","longName":"3446562","preferredDefinition":"Stage IA includes: T1a, N0, M0.  T1a: For leiomyosarcoma and endometrial stromal sarcoma: tumor 5 cm or less in greatest dimension.  For adenosarcoma: tumor limited to endometrium/endocervix.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  (AJCC 7th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IA Uterine Sarcoma AJCC v7","conceptCode":"C87132","definition":"Stage IA includes: T1a, N0, M0.  T1a: For leiomyosarcoma and endometrial stromal sarcoma: tumor 5 cm or less in greatest dimension.  For adenosarcoma: tumor limited to endometrium/endocervix.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  (AJCC 7th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BEFD3837-B694-9AD8-E040-BB89AD431C21","latestVersionIndicator":"Yes","beginDate":"2012-05-01","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-05-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BEFD3837-B6AD-9AD8-E040-BB89AD431C21","beginDate":"2012-05-01","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-05-01","modifiedBy":"ONEDATA","dateModified":"2012-05-01","deletedIndicator":"No"},{"value":"IB","valueDescription":"Stage IB Uterine Sarcoma","ValueMeaning":{"publicId":"3446564","version":"1","preferredName":"Stage IB Uterine Sarcoma","longName":"3446564","preferredDefinition":"Stage IB includes: T1b, N0, M0.  T1b: For leiomyosarcoma and endometrial stromal sarcoma: tumor more than 5 cm in greatest dimension.  For adenosarcoma: tumor invades to less than half of the myometrium.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  (AJCC 7th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IB Uterine Sarcoma AJCC v7","conceptCode":"C87133","definition":"Stage IB includes: T1b, N0, M0.  T1b: For leiomyosarcoma and endometrial stromal sarcoma: tumor more than 5 cm in greatest dimension.  For adenosarcoma: tumor invades to less than half of the myometrium.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  (AJCC 7th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BEFD3837-B6BA-9AD8-E040-BB89AD431C21","latestVersionIndicator":"Yes","beginDate":"2012-05-01","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-05-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BEFD3837-B6D3-9AD8-E040-BB89AD431C21","beginDate":"2012-05-01","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-05-01","modifiedBy":"ONEDATA","dateModified":"2012-05-01","deletedIndicator":"No"},{"value":"II","valueDescription":"Stage II Uterine Sarcoma","ValueMeaning":{"publicId":"3446566","version":"1","preferredName":"Stage II Uterine Sarcoma","longName":"3446566","preferredDefinition":"Stage II includes: T2, N0, M0.  T2: Tumor extends beyond the uterus, within the pelvis.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  This staging applies to leiomyosarcoma, endometrial stromal sarcoma, and adenosarcoma. (AJCC 7th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage II Uterine Sarcoma AJCC v7","conceptCode":"C8259","definition":"Stage II includes: T2, N0, M0.  T2: Tumor extends beyond the uterus, within the pelvis.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  This staging applies to leiomyosarcoma, endometrial stromal sarcoma, and adenosarcoma. (AJCC 7th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BEFD3837-B6E0-9AD8-E040-BB89AD431C21","latestVersionIndicator":"Yes","beginDate":"2012-05-01","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-05-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BEFD3837-B6F9-9AD8-E040-BB89AD431C21","beginDate":"2012-05-01","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-05-01","modifiedBy":"ONEDATA","dateModified":"2012-05-01","deletedIndicator":"No"},{"value":"IIIA","valueDescription":"Stage IIIA Uterine Sarcoma","ValueMeaning":{"publicId":"3446568","version":"1","preferredName":"Stage IIIA Uterine Sarcoma","longName":"3446568","preferredDefinition":"Stage IIIA includes: T3a, N0, M0.  T3a: Tumor infiltrates abdominal tissues, one side. N0: No regional lymph node metastasis. M0: No distant metastasis.  This staging applies to leiomyosarcoma, endometrial stromal sarcoma, and adenosarcoma. (AJCC 7th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IIIA Uterine Sarcoma AJCC v7","conceptCode":"C87135","definition":"Stage IIIA includes: T3a, N0, M0.  T3a: Tumor infiltrates abdominal tissues, one side. N0: No regional lymph node metastasis. M0: No distant metastasis.  This staging applies to leiomyosarcoma, endometrial stromal sarcoma, and adenosarcoma. (AJCC 7th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BEFD3837-B706-9AD8-E040-BB89AD431C21","latestVersionIndicator":"Yes","beginDate":"2012-05-01","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-05-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BEFD3837-B71F-9AD8-E040-BB89AD431C21","beginDate":"2012-05-01","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-05-01","modifiedBy":"ONEDATA","dateModified":"2012-05-01","deletedIndicator":"No"},{"value":"IIIB","valueDescription":"Stage IIIB Uterine Sarcoma","ValueMeaning":{"publicId":"3446570","version":"1","preferredName":"Stage IIIB Uterine Sarcoma","longName":"3446570","preferredDefinition":"Stage IIIB includes: T3b, N0, M0. T3b: Tumor infiltrates abdominal tissues, more than one side.  N0: No regional lymph node metastasis. M0: No distant metastasis.  This staging applies to leiomyosarcoma, endometrial stromal sarcoma, and adenosarcoma. (AJCC 7th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IIIB Uterine Sarcoma AJCC v7","conceptCode":"C87137","definition":"Stage IIIB includes: T3b, N0, M0. T3b: Tumor infiltrates abdominal tissues, more than one side.  N0: No regional lymph node metastasis. M0: No distant metastasis.  This staging applies to leiomyosarcoma, endometrial stromal sarcoma, and adenosarcoma. (AJCC 7th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BEFD3837-B72C-9AD8-E040-BB89AD431C21","latestVersionIndicator":"Yes","beginDate":"2012-05-01","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-05-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BEFD3837-B745-9AD8-E040-BB89AD431C21","beginDate":"2012-05-01","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-05-01","modifiedBy":"ONEDATA","dateModified":"2012-05-01","deletedIndicator":"No"},{"value":"IIIC","valueDescription":"Stage IIIC Uterine Sarcoma","ValueMeaning":{"publicId":"3446572","version":"1","preferredName":"Stage IIIC Uterine Sarcoma","longName":"3446572","preferredDefinition":"Stage IIIC includes: T1-T3, N1, M0.  T1: Tumor limited to the uterus. T2: Tumor extends beyond the uterus, within the pelvis.  T3: Tumor infiltrates abdominal tissues.  N1: Regional lymph node metastasis.  M0: No distant metastasis.  This staging applies to leiomyosarcoma, endometrial stromal sarcoma, and adenosarcoma. (AJCC 7th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IIIC Uterine Sarcoma AJCC v7","conceptCode":"C87138","definition":"Stage IIIC includes: T1-T3, N1, M0.  T1: Tumor limited to the uterus. T2: Tumor extends beyond the uterus, within the pelvis.  T3: Tumor infiltrates abdominal tissues.  N1: Regional lymph node metastasis.  M0: No distant metastasis.  This staging applies to leiomyosarcoma, endometrial stromal sarcoma, and adenosarcoma. (AJCC 7th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BEFD3837-B752-9AD8-E040-BB89AD431C21","latestVersionIndicator":"Yes","beginDate":"2012-05-01","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-05-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BEFD3837-B76B-9AD8-E040-BB89AD431C21","beginDate":"2012-05-01","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-05-01","modifiedBy":"ONEDATA","dateModified":"2012-05-01","deletedIndicator":"No"},{"value":"IVA","valueDescription":"Stage IVA Uterine Sarcoma","ValueMeaning":{"publicId":"3446574","version":"1","preferredName":"Stage IVA Uterine Sarcoma","longName":"3446574","preferredDefinition":"Stage IVA includes: T4, Any N, M0. T4: Tumor involves bladder or rectum.  M0: No distant metastasis.  This staging applies to leiomyosarcoma, endometrial stromal sarcoma, and adenosarcoma. (AJCC 7th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IVA Uterine Sarcoma AJCC v7","conceptCode":"C87140","definition":"Stage IVA includes: T4, Any N, M0. T4: Tumor involves bladder or rectum.  M0: No distant metastasis.  This staging applies to leiomyosarcoma, endometrial stromal sarcoma, and adenosarcoma. (AJCC 7th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BEFD3837-B778-9AD8-E040-BB89AD431C21","latestVersionIndicator":"Yes","beginDate":"2012-05-01","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-05-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BEFD3837-B791-9AD8-E040-BB89AD431C21","beginDate":"2012-05-01","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-05-01","modifiedBy":"ONEDATA","dateModified":"2012-05-01","deletedIndicator":"No"},{"value":"IVB","valueDescription":"Stage IVB Uterine Sarcoma","ValueMeaning":{"publicId":"3446576","version":"1","preferredName":"Stage IVB Uterine Sarcoma","longName":"3446576","preferredDefinition":"Stage IVB includes: Any T, Any N, M1.  M1: Distal metastasis (excluding adnexa, pelvic and abdominal tissues).  This staging applies to leiomyosarcoma, endometrial stromal sarcoma, and adenosarcoma. (AJCC 7th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IVB Uterine Sarcoma AJCC v7","conceptCode":"C87144","definition":"Stage IVB includes: Any T, Any N, M1.  M1: Distal metastasis (excluding adnexa, pelvic and abdominal tissues).  This staging applies to leiomyosarcoma, endometrial stromal sarcoma, and adenosarcoma. (AJCC 7th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BEFD3837-B79E-9AD8-E040-BB89AD431C21","latestVersionIndicator":"Yes","beginDate":"2012-05-01","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-05-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BEFD3837-B7B7-9AD8-E040-BB89AD431C21","beginDate":"2012-05-01","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-05-01","modifiedBy":"ONEDATA","dateModified":"2012-05-01","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3446557","version":"1","preferredName":"Uterine Corpus Sarcoma American Joint Committee on Cancer Stage Grouping Stage","preferredDefinition":"A malignant mesenchymal tumor arising from the wall of the uterine corpus (uterine body).  The most representative examples are leiomyosarcoma and endometrial stromal sarcoma. -- 2004:A group formed for the purpose of developing a system of clinical staging for cancer that is acceptable to the American medical profession and is compatible with other accepted classifications.:An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage.:The extent of a cancer within the body, especially whether the disease has spread from the original site to other parts of the body.","longName":"C6339:C39315:C38027:C16899","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Uterine Corpus Sarcoma","conceptCode":"C6339","definition":"A malignant mesenchymal neoplasm arising from the wall of the uterine corpus (uterine body).  The most representative examples are leiomyosarcoma and endometrial stromal sarcoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"American Joint Committee on Cancer","conceptCode":"C39315","definition":"A group formed for the purpose of developing a system of clinical staging for cancer that is acceptable to the American medical profession and is compatible with other accepted classifications.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Stage Grouping","conceptCode":"C38027","definition":"An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage, as well as prognostic parameters for specific cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Neoplasm Stage","conceptCode":"C16899","definition":"The extent of a cancer in the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BEFD3837-B642-9AD8-E040-BB89AD431C21","latestVersionIndicator":"Yes","beginDate":"2012-05-01","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-05-01","modifiedBy":"ONEDATA","dateModified":"2012-05-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BEFD3837-B653-9AD8-E040-BB89AD431C21","latestVersionIndicator":"Yes","beginDate":"2012-05-01","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-05-01","modifiedBy":"COOPERM","dateModified":"2012-05-07","changeDescription":"Created for CRF standard harmonization. Released per final community approval. mc 5/7/12","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2192345","version":"1","longName":"Data Standards","context":"NCIP","ClassificationSchemeItems":[{"publicId":"2859963","version":"1","longName":"Standard CRFs","context":"NCIP"},{"publicId":"3434437","version":"1","longName":"Staging/Extent of Disease (by Disease)","context":"NCIP"},{"publicId":"3444895","version":"1","longName":"Corpus Uteri Sarcoma","context":"NCIP"}]},{"publicId":"3461150","version":"1","longName":"Staging","context":"NCIP","ClassificationSchemeItems":[{"publicId":"3461151","version":"1","longName":"AJCC Edition 7","context":"NCIP"}]},{"publicId":"5574838","version":"1","longName":"Staging/Extent of Disease","context":"NCI Standards","ClassificationSchemeItems":[{"publicId":"10000596","version":"1","longName":"AJCC Edition 7","context":"NCI Standards"},{"publicId":"5777522","version":"1","longName":"LMS Endo SS","context":"NCI Standards"}]}],"AlternateNames":[{"name":"LCC","type":"USED_BY","context":"LCC"},{"name":"AECC","type":"USED_BY","context":"AECC"},{"name":"CITN","type":"USED_BY","context":"CITN"},{"name":"PBTC","type":"USED_BY","context":"PBTC"},{"name":"OHSU Knight","type":"USED_BY","context":"OHSU Knight"}],"ReferenceDocuments":[{"name":"Disease Stage","type":"Preferred Question Text","description":"Disease Stage","url":null,"context":"NCI Standards"}],"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","workflowStatus":"RELEASED","registrationStatus":"Preferred Standard","id":"BEFF432D-9DED-5ACA-E040-BB89AD436978","latestVersionIndicator":"Yes","beginDate":"2012-05-01","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-05-01","modifiedBy":"HARTLEYG","dateModified":"2021-06-17","changeDescription":"Created for CRF standard harmonization. Released per final community approval. mc 5/7/12","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}